Fibrinogen - Grifols

Drug Profile

Fibrinogen - Grifols

Alternative Names: FIB-Grifols; Fibrinogen human - Grifols; Human plasma-derived fibrinogen concentrate - Grifols

Latest Information Update: 16 May 2016

Price : $50

At a glance

  • Originator Grifols
  • Class Acute-phase proteins; Antihaemorrhagics; Blood coagulation factors; Coagulants
  • Mechanism of Action Fibrinogen replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Afibrinogenaemia

Most Recent Events

  • 01 May 2016 Phase-I/II clinical trials in Afibrinogenaemia in India, USA (IV) (NCT02281500)
  • 24 Oct 2014 Preclinical trials in Afibrinogenaemia in USA (IV)
  • 24 Oct 2014 Grifols plans a phase I/II trial for Afibrinogenaemia in USA (NCT02281500)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top